Imagen de Portada

NGS-Guided Precision Oncology in Breast Cancer and Gynecological Tumors : A Retrospective Molecular Tumor Board Analysis

Identifying the mutational landscape of tumors using next-generation sequencing (NGS) has become substantially more common over the past decade, especially in patients with advanced tumors. However, there is still limited real-world evidence for the clinical benefits of NGS-guided precision oncol...

Descripción completa

Guardado en:
Autores principales: Gremke, Niklas, Rodepeter, Fiona R., Teply-Szymanski, Julia, Griewing, Sebastian, Boekhoff, Jelena, Stroh, Alina, Tarawneh, Thomas S., Riera-Knorrenschild, Jorge, Balser, Christina, Hattesohl, Akira, Middeke, Martin, Ross, Petra, Litmeyer, Anne-Sophie, Romey, Marcel, Stiewe, Thorsten, Wündisch, Thomas, Neubauer, Andreas, Denkert, Carsten, Wagner, Uwe, Mack, Elisabeth K. M.
Formato: Artículo
Lenguaje:inglés
Publicado: Philipps-Universität Marburg 2024
Materias:
precision oncology
next-generation sequencing
breast cancer
Medizin
gynecological tumors; molecular tumor board
Medical sciences Medicine
Acceso en línea:Texto Completo PDF
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Identifying the mutational landscape of tumors using next-generation sequencing (NGS) has become substantially more common over the past decade, especially in patients with advanced tumors. However, there is still limited real-world evidence for the clinical benefits of NGS-guided precision oncology. This retrospective analysis of breast and gynecological cancer patients referred to our center’s multidisciplinary Molecular Tumor Board revealed that treatment recommendations were provided to 63.3% of patients, of whom 29.1% received molecular-matched treatment resulting in significantly prolonged progression-free survival. Commonly altered genes included TP53, PIK3CA, BRCA1/2, and ARID1A. Overall, NGS-guided precision oncology using panel diagnostics demonstrated improved clinical outcomes in a subset of patients with breast and gynecological cancers in a real-world setting.
Notas:Gefördert durch den Open-Access-Publikationsfonds der UB Marburg.
Descripción Física:17 Seiten
DOI:10.3390/cancers16081561

Ejemplares similares